The increase in older adults and active lifestyles has made chondral and osteochondral lesions common in the population, making them one of the central challenges in orthopedics. Although hydrogel-based regenerative medicine offers an encouraging therapeutic option for these lesions, important obstacles still prevent these therapies from reaching the clinic. In view of these factors, we adopted a risk-based approach for this review, in line with the current legislative requirements in clinical translation and clinical trials. We identified the factors that could undermine patient safety or lead to poor outcomes. Then, we outlined solutions to remedy these problems that integrate hydrogel technology, clinical/pharmaceutical/surgical protocols, and post-operative follow-up. Upcoming studies should give priority to the development of hydrogel scaffolds modified to mimic cartilage’s mechanical and physicochemical properties, together with patient-specific features. Other crucial characteristics are host-tissue integration, long-lasting cartilage tissue regeneration, and a positive outcome. In parallel, to scale complex and costly innovations, efforts should focus on a harmonized, simplified legislative landscape, optimized standards, and established follow-up protocols. Getting through this “valley of death” between research and innovation is strategic for reaching the clinics and the largest number of patients.
Osteoarthritis is a common joint disease mainly characterized by inflammation and pain. Some promising approaches are aimed at combating the general mechanisms of osteoarthritis development and progression by targeting specific molecules. Although scientific and clinical communities remain skeptical regarding the efficacy of nutrition in managing human diseases, several products have been recognized as capable of improving health conditions and counteracting specific chronic and inflammatory musculoskeletal disorders such as osteoarthritis. The aim of this narrative review is to present the results obtained by a search through electronic databases on the effect of glucosinolates and their breakdown products, in particular isothiocyanates, in both the prevention and complementary therapy for osteoarthritis. Even if we found a few studies on this topic, some preclinical studies demonstrated an active role of these compounds in reducing inflammation, oxidative stress, and apoptosis. A beneficial effect of a diet rich in glucoraphanin, a glucosinolate derivative, has been associated with a lower risk of developing osteoarthritis in a proof-of-principle trial. To further advance this topic, it is essential to conduct additional preclinical studies to address existing research gaps, alongside more rigorous clinical investigations, especially long-term randomized controlled trials. These efforts should focus on determining the most effective type of glucosinolate and relative metabolites in counteracting osteoarthritis progression and identifying their dose–response behavior to assess both benefits and side effects associated with their oral intake.
Postmenopausal osteoporosis is an age-related condition in which estrogen deficiency drives low-grade inflammation and oxidative stress, disrupting the homeostatic balance between bone formation and resorption. Since osteopenia represents a critical intermediate stage, preventive strategies are essential to mitigate its progression. Preclinical studies suggest that hydrogen sulfide (H2S), a gaseous mediator with antioxidant properties, protects bone metabolism by supporting osteoblast function and suppressing osteoclast activity. Building on this evidence, we conducted the first exploratory clinical trial assessing the effects of inhalation therapy with sulfurous mineral waters on systemic biomarkers in postmenopausal women with osteopenia. Thirty-eight eligible participants underwent a daily inhalation of sulfurous waters (14.6 mg/L sulfide) for 12 consecutive days. Biomarkers of oxidative stress, inflammation, and bone turnover were assessed at baseline, immediately post-treatment, and five days after cessation in the serum of patients. The treatment was well tolerated and did not cause any early adverse effect. Serum H2S levels, measured in a subset of participants, significantly increased, confirming systemic bioavailability. Sulfurous water inhalation induced a marked change in oxidative stress, with malondialdehyde levels declining by up to 37% from baseline. Pro-inflammatory cytokines, particularly IL-8 and MIP-1α, were significantly decreased (up to 50–70%) at the end of the treatment. Reference bone turnover markers P1NP and CTX-1 did not show significant changes; however, BALP exhibited a significant increase, suggesting the activation of pathways linked to biomineralization. These findings provide preliminary human evidence that inhaled sulfurous waters enhance systemic H2S bioavailability and modulate redox and inflammatory pathways associated with bone remodeling in osteopenic women, supporting the rationale for further controlled pharmacodynamic investigations evaluating the potential of H2S in bone health.